Alkermes plc (ALKS)
USD 27.98
(-5.12%)
USD 27.98
(-5.12%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 414.12 Million USD | 391.09% |
| 2022 | -142.26 Million USD | -433.63% |
| 2021 | -26.66 Million USD | 76.29% |
| 2020 | -112.42 Million USD | 30.63% |
| 2019 | -162.07 Million USD | -63.5% |
| 2018 | -99.12 Million USD | 32.98% |
| 2017 | -147.9 Million USD | 29.12% |
| 2016 | -208.66 Million USD | 6.97% |
| 2015 | -224.3 Million USD | -157.39% |
| 2014 | -87.14 Million USD | -206.52% |
| 2013 | 81.81 Million USD | 192.67% |
| 2012 | -88.28 Million USD | -93.47% |
| 2011 | -45.63 Million USD | -6.03% |
| 2010 | -43.03 Million USD | -131.89% |
| 2009 | 134.95 Million USD | 4938.9% |
| 2008 | -2.78 Million USD | -125.26% |
| 2007 | 11.04 Million USD | -19.17% |
| 2006 | 13.66 Million USD | 118.94% |
| 2005 | -72.12 Million USD | 25.57% |
| 2004 | -96.9 Million USD | -17.85% |
| 2003 | -82.22 Million USD | -31.82% |
| 2002 | -62.37 Million USD | -108.57% |
| 2001 | -29.9 Million USD | 60.61% |
| 2000 | -75.93 Million USD | -95.92% |
| 1999 | -38.75 Million USD | -375.78% |
| 1998 | -8.14 Million USD | 53.23% |
| 1997 | -17.41 Million USD | -25.3% |
| 1996 | -13.9 Million USD | -17.8% |
| 1995 | -11.8 Million USD | 36.56% |
| 1994 | -18.6 Million USD | 56.03% |
| 1993 | -42.3 Million USD | -428.75% |
| 1992 | -8 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 43.3 Million USD | -20.72% |
| 2024 Q3 | 104.75 Million USD | -4.67% |
| 2024 Q2 | 109.88 Million USD | 153.72% |
| 2023 Q4 | 54.63 Million USD | 24.59% |
| 2023 Q1 | -47.49 Million USD | -130.76% |
| 2023 Q2 | 239.19 Million USD | 603.63% |
| 2023 FY | 414.12 Million USD | 391.09% |
| 2023 Q3 | 43.84 Million USD | -81.67% |
| 2022 FY | -142.26 Million USD | -433.63% |
| 2022 Q1 | -26.58 Million USD | -886.07% |
| 2022 Q2 | -34.45 Million USD | -29.61% |
| 2022 Q3 | -60.64 Million USD | -75.99% |
| 2022 Q4 | -20.58 Million USD | 66.06% |
| 2021 Q1 | -16.43 Million USD | 46.53% |
| 2021 FY | -26.66 Million USD | 76.29% |
| 2021 Q2 | 4.42 Million USD | 126.9% |
| 2021 Q3 | -19.65 Million USD | -544.67% |
| 2021 Q4 | 3.38 Million USD | 117.2% |
| 2020 Q1 | -37.37 Million USD | -276.18% |
| 2020 Q2 | -33.66 Million USD | 9.93% |
| 2020 Q3 | -10.66 Million USD | 68.31% |
| 2020 Q4 | -30.72 Million USD | -188.08% |
| 2020 FY | -112.42 Million USD | 30.63% |
| 2019 Q3 | -53.62 Million USD | -49.27% |
| 2019 Q2 | -35.92 Million USD | 52.73% |
| 2019 FY | -162.07 Million USD | -63.5% |
| 2019 Q1 | -76 Million USD | -380105.0% |
| 2019 Q4 | -9.93 Million USD | 81.47% |
| 2018 Q3 | -37.15 Million USD | -36329.41% |
| 2018 Q1 | -61.88 Million USD | -1160.63% |
| 2018 FY | -99.12 Million USD | 32.98% |
| 2018 Q4 | 20 Thousand USD | 100.05% |
| 2018 Q2 | -102 Thousand USD | 99.84% |
| 2017 Q4 | 5.83 Million USD | 115.21% |
| 2017 FY | -147.9 Million USD | 29.12% |
| 2017 Q1 | -70.87 Million USD | -201.1% |
| 2017 Q2 | -44.5 Million USD | 37.2% |
| 2017 Q3 | -38.35 Million USD | 13.82% |
| 2016 Q4 | -23.53 Million USD | 61.49% |
| 2016 Q3 | -61.12 Million USD | -29.73% |
| 2016 FY | -208.66 Million USD | 6.97% |
| 2016 Q2 | -47.11 Million USD | 38.72% |
| 2016 Q1 | -76.88 Million USD | -14.65% |
| 2015 Q1 | -27.3 Million USD | -74.07% |
| 2015 FY | -224.3 Million USD | -157.39% |
| 2015 Q4 | -67.05 Million USD | 13.38% |
| 2015 Q3 | -77.41 Million USD | -47.4% |
| 2015 Q2 | -52.52 Million USD | -92.33% |
| 2014 FY | -87.14 Million USD | -206.52% |
| 2014 Q1 | -15.89 Million USD | -241.33% |
| 2014 Q2 | -22.82 Million USD | -43.62% |
| 2014 Q4 | -15.68 Million USD | 52.08% |
| 2014 Q3 | -32.73 Million USD | -43.43% |
| 2013 Q3 | -3.87 Million USD | -128.66% |
| 2013 Q1 | 18.98 Million USD | -24.85% |
| 2013 FY | 81.81 Million USD | 192.67% |
| 2013 Q4 | 11.24 Million USD | 389.97% |
| 2013 Q2 | 13.52 Million USD | -28.73% |
| 2012 FY | -88.28 Million USD | -93.47% |
| 2012 Q4 | 25.26 Million USD | 365.71% |
| 2012 Q3 | 5.42 Million USD | -83.13% |
| 2012 Q2 | 32.14 Million USD | 155.74% |
| 2012 Q1 | -57.66 Million USD | -1061.02% |
| 2011 Q3 | -11.76 Million USD | 15.27% |
| 2011 Q4 | -4.96 Million USD | 57.77% |
| 2011 FY | -45.63 Million USD | -6.03% |
| 2011 Q2 | -13.88 Million USD | -2.07% |
| 2011 Q1 | -13.6 Million USD | -14.22% |
| 2010 FY | -43.03 Million USD | -131.89% |
| 2010 Q1 | -18.55 Million USD | -197.47% |
| 2010 Q4 | -11.9 Million USD | -69.35% |
| 2010 Q3 | -7.03 Million USD | 46.27% |
| 2010 Q2 | -13.08 Million USD | 29.44% |
| 2009 Q2 | -10.02 Million USD | 24.48% |
| 2009 Q1 | -13.27 Million USD | -111.76% |
| 2009 FY | 134.95 Million USD | 4938.9% |
| 2009 Q4 | -6.23 Million USD | 24.17% |
| 2009 Q3 | -8.22 Million USD | 17.96% |
| 2008 Q1 | -17.76 Million USD | -649.11% |
| 2008 Q3 | 3.85 Million USD | -87.77% |
| 2008 Q4 | 112.88 Million USD | 2831.39% |
| 2008 FY | -2.78 Million USD | -125.26% |
| 2008 Q2 | 31.49 Million USD | 277.22% |
| 2007 Q4 | -2.37 Million USD | -136.06% |
| 2007 Q2 | 10.77 Million USD | 154.7% |
| 2007 Q1 | 4.23 Million USD | 34.24% |
| 2007 FY | 11.04 Million USD | -19.17% |
| 2007 Q3 | 6.57 Million USD | -38.95% |
| 2006 Q4 | 3.15 Million USD | -18.24% |
| 2006 Q3 | 3.85 Million USD | 2096.89% |
| 2006 Q2 | -193 Thousand USD | -102.94% |
| 2006 Q1 | 6.55 Million USD | 86.92% |
| 2006 FY | 13.66 Million USD | 118.94% |
| 2005 FY | -72.12 Million USD | 25.57% |
| 2005 Q4 | 3.5 Million USD | -74.67% |
| 2005 Q1 | -12.69 Million USD | -53.46% |
| 2005 Q2 | -10.25 Million USD | 19.22% |
| 2005 Q3 | 13.84 Million USD | 235.07% |
| 2004 Q4 | -8.27 Million USD | 42.26% |
| 2004 Q1 | -24.21 Million USD | -17.92% |
| 2004 FY | -96.9 Million USD | -17.85% |
| 2004 Q2 | -36.83 Million USD | -52.12% |
| 2004 Q3 | -14.32 Million USD | 61.11% |
| 2003 Q1 | -16.69 Million USD | -22.63% |
| 2003 Q3 | -26.43 Million USD | -2.83% |
| 2003 Q4 | -20.53 Million USD | 22.33% |
| 2003 FY | -82.22 Million USD | -31.82% |
| 2003 Q2 | -25.71 Million USD | -54.03% |
| 2002 FY | -62.37 Million USD | -108.57% |
| 2002 Q4 | -13.61 Million USD | 56.91% |
| 2002 Q1 | -19.82 Million USD | -13.49% |
| 2002 Q2 | -20.32 Million USD | -2.49% |
| 2002 Q3 | -31.59 Million USD | -55.45% |
| 2001 FY | -29.9 Million USD | 60.61% |
| 2001 Q3 | -14.49 Million USD | -37.33% |
| 2001 Q1 | -14.33 Million USD | -36.52% |
| 2001 Q2 | -10.55 Million USD | 26.34% |
| 2001 Q4 | -17.47 Million USD | -20.51% |
| 2000 Q2 | 6.56 Million USD | 117.17% |
| 2000 FY | -75.93 Million USD | -95.92% |
| 2000 Q4 | -10.49 Million USD | 9.79% |
| 2000 Q1 | -38.2 Million USD | -131.83% |
| 2000 Q3 | -11.63 Million USD | -277.38% |
| 1999 FY | -38.75 Million USD | -375.78% |
| 1999 Q3 | -13.7 Million USD | -81.68% |
| 1999 Q2 | -7.54 Million USD | 75.17% |
| 1999 Q1 | -30.39 Million USD | -1875.17% |
| 1999 Q4 | -16.47 Million USD | -20.2% |
| 1998 Q1 | -1.39 Million USD | 46.78% |
| 1998 FY | -8.14 Million USD | 53.23% |
| 1998 Q4 | -1.53 Million USD | 29.56% |
| 1998 Q3 | -2.18 Million USD | 52.91% |
| 1998 Q2 | -4.63 Million USD | -233.21% |
| 1997 Q1 | -4.45 Million USD | -16.16% |
| 1997 FY | -17.41 Million USD | -25.3% |
| 1997 Q4 | -2.61 Million USD | -378.26% |
| 1997 Q3 | -547.05 Thousand USD | 84.76% |
| 1997 Q2 | -3.59 Million USD | 19.43% |
| 1996 Q3 | -4.48 Million USD | 3.23% |
| 1996 Q4 | -3.83 Million USD | 14.49% |
| 1996 Q2 | -4.63 Million USD | 9.09% |
| 1996 Q1 | -5.1 Million USD | -64.52% |
| 1996 FY | -13.9 Million USD | -17.8% |
| 1995 Q2 | -2.6 Million USD | -8.33% |
| 1995 Q1 | -2.4 Million USD | -14.29% |
| 1995 Q4 | -3.1 Million USD | 0.0% |
| 1995 FY | -11.8 Million USD | 36.56% |
| 1995 Q3 | -3.1 Million USD | -19.23% |
| 1994 FY | -18.6 Million USD | 56.03% |
| 1994 Q4 | -2.1 Million USD | 36.36% |
| 1994 Q3 | -3.3 Million USD | 15.38% |
| 1994 Q2 | -3.9 Million USD | 7.14% |
| 1994 Q1 | -4.2 Million USD | 19.23% |
| 1993 Q4 | -5.2 Million USD | -33.33% |
| 1993 Q1 | -35.4 Million USD | -1120.69% |
| 1993 FY | -42.3 Million USD | -428.75% |
| 1993 Q2 | -5.1 Million USD | 85.59% |
| 1993 Q3 | -3.9 Million USD | 23.53% |
| 1992 Q3 | -2.7 Million USD | -80.0% |
| 1992 FY | -8 Million USD | 0.0% |
| 1992 Q2 | -1.5 Million USD | 83.33% |
| 1992 Q1 | -9 Million USD | -1385.71% |
| 1992 Q4 | -2.9 Million USD | -7.41% |
| 1991 Q4 | 700 Thousand USD | 143.75% |
| 1991 Q2 | -1.9 Million USD | 0.0% |
| 1991 Q3 | -1.6 Million USD | 15.79% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 246.761% |
| AlloVir, Inc. | -181.33 Million USD | 328.379% |
| Aptorum Group Limited | -10.52 Million USD | 4035.275% |
| Ardelyx, Inc. | -63.27 Million USD | 754.469% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 302.009% |
| Bicycle Therapeutics plc | -189.94 Million USD | 318.021% |
| AbCellera Biologics Inc. | -237.2 Million USD | 274.583% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 341.074% |
| Chimerix, Inc. | -93.06 Million USD | 544.981% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 1018.693% |
| Elevation Oncology, Inc. | -45.44 Million USD | 1011.26% |
| Fortress Biotech, Inc. | -142.34 Million USD | 390.935% |
| Fortress Biotech, Inc. | -142.34 Million USD | 390.935% |
| Agenus Inc. | -159.54 Million USD | 359.558% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 523.897% |
| Dyadic International, Inc. | -8.22 Million USD | 5132.019% |
| ImmuCell Corporation | -5.74 Million USD | 7304.53% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 34841.779% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 408.06% |
| Lantern Pharma Inc. | -17.87 Million USD | 2416.433% |
| Immix Biopharma, Inc. | -16.14 Million USD | 2665.635% |
| Incyte Corporation | 620.52 Million USD | 33.263% |
| IO Biotech, Inc. | -91.44 Million USD | 552.874% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 667.454% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 2161.355% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 879.503% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 421.055% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 343.686% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 4971.45% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 829.615% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -3367.778% |
| ContextLogic Inc. | -328 Million USD | 226.257% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 593.508% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 208.837% |
| MiMedx Group, Inc. | 37.11 Million USD | -1015.751% |
| MEI Pharma, Inc. | 14.54 Million USD | -2747.765% |
| Novavax, Inc. | -566.51 Million USD | 173.1% |
| NextCure, Inc. | -67.63 Million USD | 712.271% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 4020.496% |
| Onconetix, Inc. | -36.03 Million USD | 1249.235% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 1092.765% |
| Opthea Limited | -191.84 Million USD | 315.865% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 15148.995% |
| Vaxcyte, Inc. | -468.04 Million USD | 188.48% |
| PDS Biotechnology Corporation | -43.04 Million USD | 1062.062% |
| Precigen, Inc. | -88.92 Million USD | 565.709% |
| Pharming Group N.V. | -4.87 Million USD | 8586.9% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 347.515% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 1491.726% |
| PureTech Health plc | -146.19 Million USD | 383.259% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 603.823% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 2120.995% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 275.775% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 2232.614% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 1803.742% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 1803.742% |
| Seer, Inc. | -103.46 Million USD | 500.261% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 251.137% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 1513.145% |
| Acelyrin, Inc. | -422.06 Million USD | 198.118% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 3211607.77% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 1193.565% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 1217.316% |
| Senti Biosciences, Inc. | -92.72 Million USD | 546.603% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 1766.889% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 460.818% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 1308.515% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 10605.25% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 13196.837% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 1354.117% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 1515.415% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 2461.149% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 709.039% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 1040.973% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 397.863% |
| ChromaDex Corporation | -5.59 Million USD | 7496.356% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 182.116% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 6103.508% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 916.921% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 456.82% |
| CRISPR Therapeutics AG | -222.53 Million USD | 286.09% |
| Precision BioSciences, Inc. | -43.73 Million USD | 1046.868% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 317.374% |
| Innoviva, Inc. | 176.7 Million USD | -134.353% |
| Jaguar Health, Inc. | -34.29 Million USD | 1307.67% |
| Summit Therapeutics Inc. | -89.73 Million USD | 561.489% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 729.757% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 675.705% |
| ESSA Pharma Inc. | -32.13 Million USD | 1388.731% |
| GlycoMimetics, Inc. | -39.27 Million USD | 1154.408% |
| GT Biopharma, Inc. | -13.57 Million USD | 3150.398% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 288.906% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 995.283% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -377.033% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 904.027% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 4267.205% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 259.487% |
| Aptose Biosciences Inc. | -52.35 Million USD | 890.973% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 2971.704% |
| Soligenix, Inc. | -7.69 Million USD | 5479.647% |
| Century Therapeutics, Inc. | -146.54 Million USD | 382.588% |
| Kura Oncology, Inc. | -165.8 Million USD | 349.766% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 543.11% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 5078.026% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 16787.439% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 6486.829% |
| Autolus Therapeutics plc | -195.02 Million USD | 312.34% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 589.176% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 662.192% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 2059.413% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 282.404% |
| GRI Bio, Inc. | -11.38 Million USD | 3736.796% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 9270.685% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 415.659% |
| IGM Biosciences, Inc. | -263.46 Million USD | 257.185% |
| INmune Bio, Inc. | -29.74 Million USD | 1492.428% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 474.381% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 1187.639% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 2691.606% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 2725.874% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 777.8% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 485.151% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 250.041% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 303.801% |
| Verastem, Inc. | -92.08 Million USD | 549.722% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 978.587% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 324.889% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 449.824% |
| Histogen Inc. | -10.64 Million USD | 3991.027% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 2776.597% |
| Surrozen, Inc. | -45.78 Million USD | 1004.592% |
| Organovo Holdings, Inc. | -15.08 Million USD | 2845.075% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 8235.615% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 798.569% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 907.35% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 1738.141% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 5525.528% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 341.776% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 954.777% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 629.534% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 2820.768% |
| Apollomics, Inc. | -54.83 Million USD | 855.229% |
| Amarin Corporation plc | -67.58 Million USD | 712.715% |
| Mesoblast Limited | -58.79 Million USD | 804.361% |
| Turnstone Biologics Corp. | -59.03 Million USD | 801.521% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 350.179% |
| Synaptogenix, Inc. | -8.31 Million USD | 5081.107% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 2939.175% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 551.65% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 8742.908% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 4789.288% |
| Exelixis, Inc. | 170.88 Million USD | -142.34% |
| Better Therapeutics, Inc. | -38.26 Million USD | 1182.332% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 367.067% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 180.082% |
| NLS Pharmaceutics AG | -11.8 Million USD | 3607.409% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 5249.55% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 1480.729% |
| Gritstone bio, Inc. | -154.63 Million USD | 367.808% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 701.388% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 2518.506% |
| Avid Bioservices, Inc. | -18.67 Million USD | 2317.165% |
| Insmed Incorporated | -709.62 Million USD | 158.358% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 2739.437% |
| MediWound Ltd. | -15.29 Million USD | 2808.45% |
| OmniAb, Inc. | -69.41 Million USD | 696.554% |
| Alector, Inc. | -151.74 Million USD | 372.916% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 483.507% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 894.128% |
| Zai Lab Limited | -366.57 Million USD | 212.971% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 230.73% |
| Aura Biosciences, Inc. | -84.99 Million USD | 587.254% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 268.686% |
| Immunic, Inc. | -99.22 Million USD | 517.365% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 389.276% |
| Veracyte, Inc. | -85.79 Million USD | 582.688% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 246.948% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 3014.3% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 6112.27% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 2303.642% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 28.424% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 1727.007% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -967.27% |
| TG Therapeutics, Inc. | 20.63 Million USD | -1907.086% |
| Galecto, Inc. | -39.9 Million USD | 1137.77% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 1084.271% |
| Fortrea Holdings Inc. | 63.1 Million USD | -556.295% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 394.864% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 1534.04% |
| XBiotech Inc. | -37.51 Million USD | 1204.031% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 701.388% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 716.987% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 483.78% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 1713.127% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 877.081% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 172.754% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 627.598% |
| Vaxxinity, Inc. | -58.28 Million USD | 810.512% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 499.312% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 1960.96% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 579.219% |
| NexImmune, Inc. | -29.19 Million USD | 1518.591% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 7468.546% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 2940.075% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 89.767% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 1726.623% |
| Scopus BioPharma Inc. | -11.71 Million USD | 3635.009% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 425.921% |
| Ainos, Inc. | -13.2 Million USD | 3235.768% |
| Pluri Inc. | -22.15 Million USD | 1968.95% |
| Prothena Corporation plc | -191.03 Million USD | 316.777% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 400.006% |
| Celularity Inc. | -192.28 Million USD | 315.367% |
| Rallybio Corporation | -78.93 Million USD | 624.657% |
| Cue Biopharma, Inc. | -52.14 Million USD | 894.113% |
| MeiraGTx Holdings plc | -137.06 Million USD | 402.144% |
| Omeros Corporation | -164.53 Million USD | 351.7% |
| Humacyte, Inc. | -100.04 Million USD | 513.927% |
| Immunocore Holdings plc | -59.64 Million USD | 794.265% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 2331.381% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 1791.468% |
| Blueprint Medicines Corporation | -486.27 Million USD | 185.162% |
| CalciMedica, Inc. | -21.87 Million USD | 1993.129% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 654.677% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 414.958% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 341.76% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 226.682% |
| Pulmatrix, Inc. | -14.74 Million USD | 2909.512% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 1258.545% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 566.007% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 180.367% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 713.051% |
| Cytokinetics, Incorporated | -496.2 Million USD | 183.458% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 1303.178% |
| Nutriband Inc. | -4.87 Million USD | 8600.17% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 1049.538% |
| Vor Biopharma Inc. | -126.03 Million USD | 428.574% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 90.238% |
| Evogene Ltd. | -26.39 Million USD | 1669.179% |
| ProKidney Corp. | -151.52 Million USD | 373.308% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 741.701% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 5483.632% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 168.183% |
| CorMedix Inc. | -48.95 Million USD | 945.876% |
| BioLineRx Ltd. | -49.69 Million USD | 933.344% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 462.714% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 1187.734% |
| Atai Life Sciences N.V. | -125.47 Million USD | 430.054% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 607.258% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 608.693% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 266.322% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 1447.176% |
| MediciNova, Inc. | -9.9 Million USD | 4282.939% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 427.698% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 5817.975% |
| GeoVax Labs, Inc. | -26.74 Million USD | 1648.528% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 278.636% |
| Biomea Fusion, Inc. | -126.13 Million USD | 428.316% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 218.523% |
| Mereo BioPharma Group plc | -28.41 Million USD | 1557.355% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 316.717% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 280.089% |
| Absci Corporation | -115.51 Million USD | 458.501% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 1601.149% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 466.911% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 271.01% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 1743.602% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 299.103% |
| Allakos Inc. | -196.05 Million USD | 311.226% |
| Imunon, Inc. | -21.03 Million USD | 2069.156% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 474.216% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -286.013% |
| BioAtla, Inc. | -129.68 Million USD | 419.324% |
| NLS Pharmaceutics AG | -11.8 Million USD | 3607.409% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 2713.912% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 226.358% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 1091.719% |
| XOMA Corporation | -41.84 Million USD | 1089.586% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 493.514% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 440.855% |
| aTyr Pharma, Inc. | -54.91 Million USD | 854.06% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 573.677% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 339.557% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 262.752% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 2029.2% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 5142.425% |
| Akari Therapeutics, Plc | -16.8 Million USD | 2564.132% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 4683132.852% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -22.676% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 6437.934% |
| UroGen Pharma Ltd. | -65.53 Million USD | 731.9% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 563.857% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 5801.794% |
| Orgenesis Inc. | -53.63 Million USD | 872.097% |
| Entera Bio Ltd. | -8.89 Million USD | 4757.766% |
| GH Research PLC | -41.22 Million USD | 1104.614% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 1710.868% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 598.624% |
| Xencor, Inc. | -138.63 Million USD | 398.705% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 8134.054% |
| Replimune Group, Inc. | -234.77 Million USD | 276.393% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 2026.945% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 3068.191% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 6437.934% |
| Portage Biotech Inc. | -18.25 Million USD | 2368.789% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 5817.975% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 494.548% |
| OncoCyte Corporation | -25.13 Million USD | 1747.525% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 3763.222% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 3714.557% |
| Purple Biotech Ltd. | 22.27 Million USD | -1759.467% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 5612.806% |
| scPharmaceuticals Inc. | -55.39 Million USD | 847.567% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 2291.389% |
| HilleVax, Inc. | -133.34 Million USD | 410.564% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 3536.982% |
| Tharimmune, Inc. | -9.45 Million USD | 4479.824% |
| Genprex, Inc. | -31.07 Million USD | 1432.629% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 320.051% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 1419.827% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 54233.595% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 7702.867% |
| OKYO Pharma Limited | -15.74 Thousand USD | 2629491.107% |
| Savara Inc. | -60 Million USD | 790.123% |
| Curis, Inc. | -48.33 Million USD | 956.828% |
| Daré Bioscience, Inc. | -30.83 Million USD | 1442.813% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 8037.508% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 5790.834% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 1619.714% |
| BeiGene, Ltd. | -1.2 Billion USD | 134.289% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 2176.913% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 185.003% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 542.192% |
| Erasca, Inc. | -141.52 Million USD | 392.614% |
| bluebird bio, Inc. | -244.26 Million USD | 269.54% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 9247.877% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -112.981% |
| DBV Technologies S.A. | -76.43 Million USD | 641.818% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 9247.877% |
| Moderna, Inc. | -4.23 Billion USD | 109.769% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 1071.912% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 6611.352% |
| Molecular Templates, Inc. | -10.46 Million USD | 4056.832% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 715.914% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 209.921% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 388.967% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 896.496% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 367.967% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 298.973% |
| MacroGenics, Inc. | -168.24 Million USD | 346.144% |
| RenovoRx, Inc. | -11.39 Million USD | 3733.924% |
| Adicet Bio, Inc. | -152.03 Million USD | 372.381% |
| Prime Medicine, Inc. | -191.29 Million USD | 316.487% |
| Aditxt, Inc. | -26.06 Million USD | 1688.962% |
| Adagene Inc. | -23.71 Million USD | 1845.887% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 5765.068% |
| Quantum-Si incorporated | -111.17 Million USD | 472.509% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 1408.525% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 2940.778% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -239.405% |
| SciSparc Ltd. | -5.77 Million USD | 7273.428% |
| Vericel Corporation | -6.46 Million USD | 6506.59% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 4883.852% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 1891.218% |
| Generation Bio Co. | -138.56 Million USD | 398.869% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 598.762% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 578.975% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 271.763% |
| Invivyd, Inc. | -207.78 Million USD | 299.305% |
| Relay Therapeutics, Inc. | -373 Million USD | 211.025% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 4515.651% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -1827.853% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 4125.683% |
| 2seventy bio, Inc. | -216.7 Million USD | 291.101% |
| ADMA Biologics, Inc. | 21.63 Million USD | -1814.395% |
| Clene Inc. | -40.54 Million USD | 1121.515% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 1819.929% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 855.752% |
| GeoVax Labs, Inc. | -26.74 Million USD | 1648.528% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 218.3% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 1227.414% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -2475.866% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 499.338% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 1317.934% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 343.203% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 160.517% |
| Evaxion Biotech A/S | -22.19 Million USD | 1965.667% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 602.685% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 285.602% |
| Trevena, Inc. | -35.28 Million USD | 1273.549% |
| Surrozen, Inc. | -45.78 Million USD | 1004.592% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 618.009% |
| Cingulate Inc. | -22.75 Million USD | 1919.581% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -5427.523% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 1027.132% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 5129.451% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 503.793% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 664.36% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 767.142% |
| Clearmind Medicine Inc. | -8.74 Million USD | 4837.506% |
| Kronos Bio, Inc. | -121.83 Million USD | 439.918% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 643.496% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 14219.472% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 510.725% |
| Statera Biopharma, Inc. | -98.34 Million USD | 521.096% |
| ImmunityBio, Inc. | -362.25 Million USD | 214.319% |
| Korro Bio, Inc. | -84.53 Million USD | 589.888% |
| Kineta, Inc. | -15.72 Million USD | 2733.861% |
| BioVie Inc. | -32.17 Million USD | 1386.909% |
| Codexis, Inc. | -68.06 Million USD | 708.386% |
| Celularity Inc. | -192.28 Million USD | 315.367% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 286.032% |
| Celcuity Inc. | -66.23 Million USD | 725.275% |
| Virax Biolabs Group Limited | -6.49 Million USD | 6474.567% |
| Cibus, Inc. | -318.88 Million USD | 229.866% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 1063.074% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 1323.62% |
| IN8bio, Inc. | -30.33 Million USD | 1465.072% |
| Kodiak Sciences Inc. | -277.32 Million USD | 249.329% |
| Annexon, Inc. | -143.72 Million USD | 388.139% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 434.533% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 740.6% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 1866.431% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 217.073% |
| Eyenovia, Inc. | -25.4 Million USD | 1729.988% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -1168.756% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 7545.559% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 623.324% |
| Arcellx, Inc. | -89.88 Million USD | 560.75% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 1011.922% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 401.823% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 1431.197% |
| Moolec Science SA | -6.65 Million USD | 6323.837% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 777.356% |
| Geron Corporation | -193.94 Million USD | 313.527% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 1057.441% |
| Royalty Pharma plc | 1.49 Billion USD | 72.247% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 352.264% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 4539.622% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 1991.429% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 342.238% |
| Humacyte, Inc. | -100.04 Million USD | 513.927% |
| Structure Therapeutics Inc. | -102.77 Million USD | 502.94% |
| 89bio, Inc. | -151.2 Million USD | 373.883% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 616.8% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 2948.157% |
| Genelux Corporation | -24.16 Million USD | 1813.726% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 1320.771% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 341.119% |
| Notable Labs, Ltd. | -14.65 Million USD | 2925.421% |
| Liquidia Corporation | -73.38 Million USD | 664.322% |
| Mustang Bio, Inc. | -50.72 Million USD | 916.39% |
| Immunovant, Inc. | -282.7 Million USD | 246.483% |
| Quantum-Si incorporated | -111.17 Million USD | 472.509% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 630.225% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 2047.252% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 505.954% |
| Acasti Pharma Inc. | -11.31 Million USD | 3760.909% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 1906.728% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 2691.606% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 293.466% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 11386.832% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 2706.836% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 1520.318% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 1100.681% |
| PepGen Inc. | -84.76 Million USD | 588.547% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 1497.597% |
| United Therapeutics Corporation | 1.18 Billion USD | 65.05% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 1908.63% |
| Solid Biosciences Inc. | -104.31 Million USD | 496.992% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 1362.255% |
| Immuneering Corporation | -58.41 Million USD | 808.957% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 8235.615% |
| Silo Pharma, Inc. | -3.85 Million USD | 10840.815% |
| Belite Bio, Inc | -31.66 Million USD | 1407.699% |
| XOMA Corporation | -41.84 Million USD | 1089.586% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 713.332% |
| Bionomics Limited | -17.89 Billion USD | 102.315% |
| Apogee Therapeutics, Inc. | -93 Million USD | 545.278% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -1060.656% |
| uniQure N.V. | -282.87 Million USD | 246.4% |
| Cassava Sciences, Inc. | -105.95 Million USD | 490.84% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 5765.068% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 419.775% |
| Forte Biosciences, Inc. | -32.48 Million USD | 1374.771% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 5084.164% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 1508.818% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 7545.559% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 3014.3% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 4758.814% |
| Altimmune, Inc. | -95.92 Million USD | 531.696% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 663.477% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -1060.656% |
| Compugen Ltd. | -12.99 Million USD | 3287.515% |
| Peak Bio, Inc. | -1356.23 USD | 30534891.296% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 934.856% |
| Benitec Biopharma Inc. | -22.49 Million USD | 1941.361% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 270.911% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 1492.194% |
| Zura Bio Limited | -62.63 Million USD | 761.135% |
| PolyPid Ltd. | -22.86 Million USD | 1911.003% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 2644.372% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 1492.194% |
| Instil Bio, Inc. | -159.16 Million USD | 360.178% |
| argenx SE | -425.04 Million USD | 197.429% |
| Immunome, Inc. | -109.53 Million USD | 478.09% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 922.274% |
| Verona Pharma plc | -67.83 Million USD | 710.521% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 1689.11% |
| Shattuck Labs, Inc. | -91.95 Million USD | 550.343% |
| CervoMed Inc. | -7.81 Million USD | 5400.494% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 666.437% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 3208.791% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 959.638% |
| Moolec Science SA | -6.65 Million USD | 6323.837% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 2617.698% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 406.243% |
| AnaptysBio, Inc. | -164.41 Million USD | 351.882% |
| Design Therapeutics, Inc. | -78.19 Million USD | 629.636% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 575.778% |
| NeurAxis, Inc. | -6.66 Million USD | 6313.854% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 1122.549% |
| Lumos Pharma, Inc. | -36.61 Million USD | 1231.048% |
| Achilles Therapeutics plc | -75.25 Million USD | 650.292% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 1689.11% |
| 180 Life Sciences Corp. | -13.47 Million USD | 3172.692% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -7931.362% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 14219.472% |
| Nutriband Inc. | -4.87 Million USD | 8600.17% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 473.824% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 846.852% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 914.623% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 726.518% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 865.148% |
| Palisade Bio, Inc. | -13.07 Million USD | 3268.493% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 1011.982% |
| Beam Therapeutics Inc. | -176.48 Million USD | 334.65% |
| Neurogene Inc. | -55.58 Million USD | 845.052% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 479.392% |
| AEON Biopharma, Inc. | -48.42 Million USD | 955.112% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 528.21% |
| Sesen Bio, Inc. | -25.9 Million USD | 1698.371% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 595.782% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 3390.104% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 189.917% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 671.684% |
| Athira Pharma, Inc. | -125.46 Million USD | 430.067% |
| Vaccinex, Inc. | -22.88 Million USD | 1909.578% |
| HCW Biologics Inc. | -25.71 Million USD | 1710.294% |
| XOMA Corporation | -41.84 Million USD | 1089.586% |
| Nektar Therapeutics | -137.42 Million USD | 401.344% |
| Arvinas, Inc. | -401.5 Million USD | 203.144% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 4683132.852% |
| Merus N.V. | -156.54 Million USD | 364.535% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 513.044% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 1296.193% |
| Rezolute, Inc. | -70.42 Million USD | 688.049% |
| Clene Inc. | -40.54 Million USD | 1121.515% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 2628.453% |
| BeyondSpring Inc. | -23.11 Million USD | 1891.65% |
| Synlogic, Inc. | -55.16 Million USD | 850.751% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 2409.789% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 3925.961% |
| Peak Bio, Inc. | -1356.23 USD | 30534891.296% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 1122.448% |
| Krystal Biotech, Inc. | -109.72 Million USD | 477.411% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 419.687% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 220.731% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 8825.792% |
| MannKind Corporation | 8.67 Million USD | -4672.09% |
| Ikena Oncology, Inc. | -75.41 Million USD | 649.11% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 4392.754% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 715.978% |
| Gossamer Bio, Inc. | -183.75 Million USD | 325.361% |
| CohBar, Inc. | -12.38 Million USD | 3442.848% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 916.422% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 1601.149% |
| Legend Biotech Corporation | -439.48 Million USD | 194.229% |
| Mural Oncology plc | -194.63 Million USD | 312.765% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 716.776% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 2664.974% |
| Disc Medicine, Inc. | -91.12 Million USD | 554.455% |
| Champions Oncology, Inc. | -7.35 Million USD | 5729.717% |
| REGENXBIO Inc. | -268.12 Million USD | 254.449% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 3963.732% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 842.74% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 1162.924% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 462.131% |
| Vaxart, Inc. | -83.34 Million USD | 596.865% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 4960.582% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 1067.709% |
| Cellectis S.A. | -106.62 Million USD | 488.387% |
| Longeveron Inc. | -21.02 Million USD | 2069.29% |
| Repare Therapeutics Inc. | -116.22 Million USD | 456.314% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 254.625% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 647.455% |
| Revolution Medicines, Inc. | -487.18 Million USD | 185.003% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 6325.526% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 1042.171% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 655.198% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 694.704% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 3860.984% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 90.386% |
| Denali Therapeutics Inc. | -196.69 Million USD | 310.536% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 4883.852% |
| Veru Inc. | -93.78 Million USD | 541.578% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 1875.138% |
| Cingulate Inc. | -22.75 Million USD | 1919.581% |
| Passage Bio, Inc. | -108.38 Million USD | 482.07% |
| Context Therapeutics Inc. | -25.07 Million USD | 1751.69% |
| Exicure, Inc. | -14.99 Million USD | 2861.55% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 300.968% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 1120.055% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 4361.857% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 324.63% |
| Nuvalent, Inc. | -149.49 Million USD | 377.02% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 5140.121% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 566.716% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 2093.463% |
| OmniAb, Inc. | -69.41 Million USD | 696.554% |
| Anew Medical, Inc. | -1.3 Million USD | 31934.968% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 3342.675% |
| Lipocine Inc. | -17.93 Million USD | 2409.537% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 704.443% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 643.81% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 1187.639% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 1147.694% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 1950.08% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 171.419% |
| Ocugen, Inc. | -65.53 Million USD | 731.948% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 541.184% |
| Q32 Bio Inc. | -92.1 Million USD | 549.634% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 2031.629% |
| Alumis Inc. Common Stock | -158.17 Million USD | 361.814% |
| Equillium, Inc. | -14.52 Million USD | 2951.687% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 763.593% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 5339.829% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 2295.174% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 982.03% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 481.799% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 3559.661% |
| Dominari Holdings Inc. | -21.79 Million USD | 1999.991% |
| Edesa Biotech, Inc. | -9.22 Million USD | 4590.219% |
| vTv Therapeutics Inc. | -25.5 Million USD | 1723.88% |
| Bio-Techne Corporation | 206.68 Million USD | -100.363% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 205.782% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -115.655% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 413.072% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 1178.696% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 374.07% |
| Nkarta, Inc. | -131.65 Million USD | 414.563% |
| BioCardia, Inc. | -11.64 Million USD | 3656.527% |
| Iterum Therapeutics plc | -47.46 Million USD | 972.424% |